These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26225681)

  • 21. The impact of informed consent on patient interest in prostate-specific antigen screening.
    Wolf AM; Nasser JF; Wolf AM; Schorling JB
    Arch Intern Med; 1996 Jun; 156(12):1333-6. PubMed ID: 8651843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinician Factors Associated With Prostate-Specific Antigen Screening in Older Veterans With Limited Life Expectancy.
    Tang VL; Shi Y; Fung K; Tan J; Espaldon R; Sudore R; Wong ML; Walter LC
    JAMA Intern Med; 2016 May; 176(5):654-61. PubMed ID: 27042937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
    Drazer MW; Huo D; Eggener SE
    J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
    Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
    Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
    Bunting PS; Goel V; Williams JI; Iscoe NA
    CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
    Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perceptions about screening for prostate cancer using genetic lifetime risk assessment: a qualitative study.
    Kirkegaard P; Edwards A; Nielsen TLO; Ørntoft TF; Sørensen KD; Borre M; Bro F
    BMC Fam Pract; 2018 Feb; 19(1):32. PubMed ID: 29454309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen screening for prostate cancer in older men in the United States of America.
    Black A; Berg CD
    Gerontology; 2012; 58(4):331-6. PubMed ID: 22343605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.
    Hugosson J; Godtman RA; Carlsson SV; Aus G; Grenabo Bergdahl A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
    Scand J Urol; 2018 Feb; 52(1):27-37. PubMed ID: 29254399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost implications of PSA screening differ by age.
    Rao K; Liang S; Cardamone M; Joshu CE; Marmen K; Bhavsar N; Nelson WG; Ballentine Carter H; Albert MC; Platz EA; Pollack CE
    BMC Urol; 2018 May; 18(1):38. PubMed ID: 29743049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of participation in risk-based prostate cancer screening.
    Koitsalu M; Eklund M; Adolfsson J; Sprangers MAG; Grönberg H; Brandberg Y
    PLoS One; 2018; 13(7):e0200409. PubMed ID: 29990335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
    Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
    Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perceived benefits: a predictor of participation in prostate cancer screening.
    Tingen MS; Weinrich SP; Heydt DD; Boyd MD; Weinrich MC
    Cancer Nurs; 1998 Oct; 21(5):349-57. PubMed ID: 9775485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prostate cancer screening using prostate-specific antigen: The views of general and laboratory physicians].
    Giménez N; Filella X; Gavagnach M; Allué JA; Pedrazas D; Ferrer F;
    Semergen; 2018 Sep; 44(6):409-419. PubMed ID: 29574008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program.
    Cohen L; Fouladi RT; Babaian RJ; Bhadkamkar VA; Parker PA; Taylor CC; Smith MA; Gritz ER; Basen-Engquist K
    Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):610-7. PubMed ID: 12869399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended use of P504S positive primary circulating prostate cell detection to determine the need for initial prostate biopsy in a prostate cancer screening program in Chile.
    Murray NP; Reyes E; Fuentealba C; Jacob O; Orellana N
    Asian Pac J Cancer Prev; 2014; 15(21):9335-9. PubMed ID: 25422221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-screening Discussions and Prostate-Specific Antigen Testing for Prostate Cancer Screening.
    Li J; Zhao G; Hall IJ
    Am J Prev Med; 2015 Aug; 49(2):259-63. PubMed ID: 25997905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the Formula of PSA, Age, Prostate Volume and Race Versus PSA Density and the Detection of Primary Malignant Circulating Prostate Cells in Predicting a Positive Initial Prostate Biopsy in Chilean Men with Suspicion of Prostate Cancer.
    Murray NP; Reyes E; Fuentealba C; Orellana N; Morales F; Jacob O
    Asian Pac J Cancer Prev; 2015; 16(13):5365-70. PubMed ID: 26225679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Variation in general practice prostate-specific antigen testing and prostate cancer outcomes: an ecological study.
    Hjertholm P; Fenger-Grøn M; Vestergaard M; Christensen MB; Borre M; Møller H; Vedsted P
    Int J Cancer; 2015 Jan; 136(2):435-42. PubMed ID: 24905402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Men under the age of 55 years with screen detected prostate cancer do not have less significant disease compared to older men in a population of patients in Australia.
    Dantanarayana ND; Hossack T; Cozzi P; Brooks A; Lau H; Delprado W; Patel MI
    BMC Urol; 2015 Dec; 15():124. PubMed ID: 26715039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.